Cat. No. 0415
Chemical Name: 4-(3-Butoxy-4-methoxyphenyl)methyl-
Biological ActivityWidely used inhibitor of cyclic nucleotide phosphodiesterase, selective for PDE4 (IC50 = 2.0 μM). Also available as part of the Phosphodiesterase Inhibitor Tocriset™.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Soderling et al (1998) Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase. Proc.Natl.Acad.Sci.U.S.A. 95 8991. PMID: 9671792.
Nicholson et al (1991) Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. TiPS 12 19. PMID: 1848733.
Reeves et al (1987) The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle. Biochem.J. 241 535. PMID: 3036066.
If you know of a relevant reference for Ro 20-1724 please let us know.
Citations are publications that use Tocris products. Selected citations for Ro 20-1724 include:
Winger et al (2014) Rapid remodeling of tight junctions during paracellular diapedesis in a human model of the blood-brain barrier. J Immunol 193 2427. PMID: 25063869.
Do you know of a great paper that uses Ro 20-1724 from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Ro 20-1724, supplier, PDE4, inhibitors, inhibits, Phosphodiesterases, Ro20-1724, Tocris Bioscience, Phosphodiesterase Inhibitor products
Find multiple products by catalog number
New Products in this Area
Potent and highly selective PDE5 inhibitor; orally bioavailable7-Ethoxyresorufin
Fluorometric CYP450 substrateGaleterone
CYP17 inhibitor; also androgen receptor antagonist
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.